What VoiceMed does

VoiceMed is a digital health company developing AI-powered vocal biomarker technology to detect and monitor chronic respiratory diseases, primarily Chronic Obstructive Pulmonary Disease (COPD), using only a standard smartphone microphone. Founded in Rome in 2020 during the COVID-19 pandemic, the company analyzes acoustic features of voice, breath, and cough recordings to derive biomarkers correlated with respiratory function, validated across 1,900+ patients and 5,200+ benchmark recordings with 82.9% sensitivity and 59.3% specificity for COPD case-finding and up to 99% correlation with spirometry in controlled hospital settings. The core product portfolio comprises VoiceMed Check for COPD (a sub-minute case-finding test), VoiceMed Predict for COPD (a longitudinal exacerbation monitoring tool currently in studies), a smoking cessation feedback solution, and a commercial SDK/API enabling third-party integration; clinical products are being developed as a Class IIa medical device under EU MDR with CE mark certification in progress.

The business model is B2B-focused, monetizing through volume-based SDK/API licensing to digital health and remote patient monitoring platforms and through paid clinical pilot partnerships with pharmaceutical companies. Two paying pilots are disclosed: a six-month pilot with Chiesi Group launched in January 2026 covering COPD detection and monitoring, and a YouHealthy SDK integration. Distribution combines direct enterprise sales, embed-and-license through the SDK/API (typically integrated in one day), and the consumer Airlyn wellness app on iOS and Android. The company is legally domiciled in Luxembourg through VoiceMed Sarl with primary operations in Rome through VoiceMed S.r.l., has raised approximately €1 million in equity alongside over €500K in non-dilutive European grants, and operates with a multidisciplinary team of roughly 7-10 members spanning AI engineering, biomedical engineering, clinical affairs, and regulatory expertise.

Name

VoiceMed

Legal name

VoiceMed S.r.l.

Website

https://voicemed.io

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

1–10 employees

Short description

VoiceMed is an AI-driven digital health company building smartphone-based vocal biomarker technology for early detection and remote monitoring of chronic respiratory diseases, primarily COPD, serving pharmaceutical companies, hospitals, and digital health platforms via B2B pilots and SDK integration.

Ownership category

akta.pro rank

Product category

Digital Health Respiratory Diagnostics

NAICS

Medical and Diagnostic Laboratories (6215)

SIC

Services-Home Health Care Services (8082)

akta.pro primary industry

Respiratory & Sleep RPM (COPD, asthma, sleep apnea) (HLALAFAB)

akta.pro secondary industries

COPD & Chronic Bronchitis Management (HLAKANAE), Pulmonology & Sleep Medicine Telemedicine Platforms (HLALAGAF)

Keywords

• Vocal biomarker technology
• Respiratory disease detection
• Digital health diagnostics
• Remote patient monitoring
• AI voice analysis

Headquarters

HQ city

Luxembourg

HQ country

Luxembourg

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure

Revenue model

1. B2B software licensing / SDK deployment: VoiceMed offers its voice biomarker technology to B2B partners (pharma, digital health platforms, hospitals) via SDK/API integration. Partners pilot the technology and pay for deployment. The company also pursues Letters of Intent for early market access once CE mark certification is obtained.
2. Paid clinical research partnerships: VoiceMed conducts paid pilots with pharmaceutical and healthcare partners to validate vocal biomarker technology for specific use cases (e.g., Chiesi pilot for COPD screening and monitoring). Revenue generated through clinical collaboration agreements.
3. Airlyn App subscription: The Airlyn app, a product of VoiceMed Sarl, offers subscription services charged in advance or periodically according to the selected plan. Subscriptions automatically renew. The Airlyn app provides breathing exercises and wellness features.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

VoiceMed develops AI-powered vocal biomarker software that analyzes voice, breath, and cough sounds recorded via standard smartphone microphones to detect and monitor respiratory diseases, with primary focus on COPD. The company sells B2B solutions — VoiceMed Check for COPD (case-finding), VoiceMed Predict for COPD (exacerbation monitoring), and a smoking cessation vocal feedback product — through SDK/API integration into partner platforms (e.g., YouHealthy) and direct pilots with pharmaceutical and healthcare customers (e.g., Chiesi Group). It also offers the Airlyn consumer wellness app on iOS and Android app stores.

Product overview

VoiceMed offers a portfolio of voice-based health monitoring products centered on vocal biomarker technology. The core offerings include VoiceMed Check for COPD (early detection), VoiceMed Predict for COPD (exacerbation monitoring), and VoiceMed Check for Smoking Cessation (respiratory health feedback during quit programs). These products use acoustic analysis of voice and breath via smartphone to detect and monitor chronic respiratory diseases. The technology is accessible through VoiceMed's own apps or via SDK/API integration into third-party platforms. VoiceMed also offers Airlyn, a wellness-focused breathing exercises app. All clinical products are developed under a Class IIa medical device regulatory pathway under EU MDR, with CE mark certification planned.

Differentiator

Problem solved

Functional benefit

Brands

• VoiceMed Check for COPD: Smartphone-based test for early detection of COPD using voice and breath acoustic analysis
• VoiceMed Predict for COPD
• Airlyn
• VoiceMed Wellbeing

Products and services

• VoiceMed Check for COPD A smartphone-based AI test that analyzes voice and breathing sounds to detect signs of Chronic Obstructive Pulmonary Disease (COPD) in under a minute, without external devices or clinic visits. Targets enterprise B2B customers including primary care providers, pulmonologists, hospitals, RPM platforms, and pharmaceutical companies. Validated with 82.9% sensitivity and 59.3% specificity across 1,900+ patients.
• VoiceMed Predict for COPD A smartphone-based remote monitoring solution for COPD patients that predicts exacerbations using daily voice recordings combined with symptoms, vital signs, and treatment changes over 365 days. Designed for Remote Patient Monitoring platforms, hospitals, and pharmaceutical companies managing COPD patient populations.
• VoiceMed Check for Smoking Cessation Voice analysis technology that supports smoking cessation by offering positive, personalized feedback on perceived respiratory wellbeing based on detected vocal biomarkers. Targets adult smokers and ex-smokers (typically 40+) at elevated COPD risk, accessed via consumer apps or partner platforms.
• VoiceMed SDK/API Software Development Kit and API enabling third-party iOS and Android apps to integrate VoiceMed's vocal biomarker technology. Integration typically completes in one day, GDPR-compliant, hosted on ISO 27001-certified European infrastructure. Used by partners such as YouHealthy.
• Airlyn App A breathing exercises and respiratory wellness mobile app developed by VoiceMed Sarl, available on Google Play and Apple App Store. Positioned as a wellness/non-medical device product offering subscription services with breathing exercises and wellness features, used in clinical usability testing with up to 92% test completion rate.

Quantifiable outcome

• 82.9% sensitivity, 59.3% specificity, 55.6% PPV for COPD detection (VoiceMed Check)
• +4 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

Yes

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature6 records

Partnerships

Eight partnerships are on record, tiered flagship, core and minor.

• Chiesi GroupflagshipStrategic or Co-development Partner · 13 January 2026VoiceMed and Chiesi Group launched a six-month pilot (January 2026) to explore how VoiceMed's AI-powered vocal biomarker technology can enable early detection of chronic respiratory diseases including COPD. The collaboration combines Chiesi's expertise in respiratory therapies with VoiceMed's smartphone-based platform, evaluating improvements in patient quality of life using QALY metrics and assessing potential reductions in emergency department visits. Michelle Soriano, EVP Air Franchise at Chiesi, stated the goal is to advance digital innovation for earlier detection, proactive management, and keeping patients stable at home.
• YouHealthycoreOEM/ Whitelabel/ Licensing PartnerYouHealthy integrated VoiceMed's vocal biomarker service through the VoiceMed SDK into the YouHealthy app, enabling patients to access voice-based health checks directly from the YouHealthy platform. This is described as a paid pilot with easy integration, clear documentation, and supportive team from VoiceMed. Project Manager Maria Mercorella at YouHealthy provided positive testimonial about the integration experience.
• Humanitas Research HospitalcoreStrategic or Co-development PartnerHumanitas Research Hospital collaborated with VoiceMed on the CARE study (2023) investigating vocal characteristics in relation to respiratory health and airway responsiveness. The hospital conducted proof-of-concept studies with synchronized audio recordings and spirometry data across six stages, achieving up to 99% correlation between acoustic biomarkers and pulmonary function. Humanitas also participated in the VERA and AIPU COPD validation studies enrolling 1,900 patients. The hospital is ranked among Italy's leading research hospitals.
• San Camillo Forlanini HospitalcoreStrategic or Co-development PartnerSan Camillo Forlanini Hospital, ranked Italy's top public hospital for pneumology in the 2025 Newsweek classification, collaborated with VoiceMed on the VERA and AIPU studies (2024-2025) evaluating vocal biomarkers for COPD identification from single voice recordings. The hospital enrolled patients alongside Humanitas. In 2026, VoiceMed launched two new longitudinal studies with San Camillo following up to 1,000 COPD patients at home for 12 months to validate exacerbation prediction.
• Policlinico Umberto IcoreStrategic or Co-development PartnerPoliclinico Umberto I, one of the largest and oldest hospitals in Europe, collaborated with VoiceMed on the VOICE and BREATH studies (2026-2028) investigating whether changes in voice over time may help identify increased risk of COPD exacerbation. Patients record daily voice samples for 365 days combined with symptoms, vital signs, treatment changes, and medical visits. Advisor Matteo Bonini is University Professor and pneumologist at Policlinico Umberto I and Honorary Clinical Senior Lecturer at Imperial College London.
• LNS (National Laboratory of Luxembourg)minorStrategic or Co-development PartnerLNS (Luxembourg National Laboratory of Health) collaborated with VoiceMed on the COVID+VOICES study (2021-2022) exploring the use of voice data in relation to COVID-19 and general health. Voice recordings were combined with participant health, wellbeing, and COVID-19 status information. This study supported the development of VoiceMed's audio acquisition engine, recording quality controls, and early research into vocal biomarkers.
• ASL of TurinminorStrategic or Co-development PartnerASL of Turin collaborated with VoiceMed on the COVID+VOICES study (2021-2022) alongside LNS Luxembourg, exploring voice data in relation to COVID-19 and general health. This early clinical study supported the development of VoiceMed's audio-acquisition engine and recording-quality controls.
• General Practitioners (Netherlands)coreStrategic or Co-development PartnerVoiceMed is conducting a pivotal study (2026-2027) in collaboration with general practitioners in the Netherlands to validate VoiceMed Check for COPD in an unsupervised setting. Each participant completes one voice-recording activity and the result is compared with the final diagnosis established through the standard clinical diagnostic pathway. This study is designed to support the clinical evaluation and regulatory development of the software as a Class IIa medical device under EU MDR.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Sonde Health: Boston-based vocal biomarker platform analyzing voice for mental and respiratory health conditions via smartphone. Closest direct competitor — same technology category (AI voice biomarkers), overlapping respiratory focus, B2B licensing model.
• Kintsugi: Vocal biomarker company applying ML to short voice clips for mental health screening. Same core technology (AI on voice features), similar SDK/API B2B2C distribution, though focused on depression rather than respiratory — VoiceMed's entry into adjacent clinical domains would directly intersect.
• Hyfe AI: Cough-detection AI company analyzing cough acoustic signatures for respiratory disease screening via smartphone. Direct overlap with VoiceMed's cough/breath sound analysis and smartphone-only delivery model; competing for the same RPM and pharma channels.
• ResApp Health: Australian digital health company (acquired by Pfizer/Sanofi) that developed machine-learning algorithms to diagnose respiratory conditions from cough and breath sounds. Closest clinical-area direct peer for COPD and respiratory disease screening using audio biomarkers.
• Aural Analytics: Voice/speech biomarker platform extracting clinical-grade metrics from speech for neurological conditions (ALS, Parkinson's). Comparable technology stack and FDA-cleared SaMD pathway experience directly relevant to VoiceMed's EU MDR Class IIa ambitions.
• Ellipsis Health: Vocal biomarker company analyzing voice for anxiety and depression screening via short smartphone recordings. Same technology category (AI vocal biomarkers, SaaS B2B delivery) and similar go-to-market with health systems and payers; adjacent clinical focus.

Emerging players

• Ebenbuild: Munich-based digital-twin lung company combining patient-specific lung modeling with respiratory data. Emerging player targeting the same COPD patient population via a different (modeling-based) technology approach; competing for pharma respiratory R&D budgets.
• NuvoAir: Respiratory digital health platform combining connected spirometry with care management for COPD and asthma. Partial overlap on the COPD management value proposition; competing for the same RPM and pulmonology channel.
• TidalSense: UK-based respiratory diagnostics company using AI on lung-sound recordings (including cough) to detect and monitor COPD and asthma. Direct clinical-area overlap with VoiceMed Check, though currently more hardware-coupled (digital stethoscope).

Broad incumbents

• Propeller Health (ResMed): Now part of ResMed, Propeller Health is the dominant digital health platform for asthma and COPD, combining inhaler sensors with patient apps. Largest incumbent in the digital respiratory space — competing for the same pharma, payer, and pulmonology stakeholders.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/VoiceMed
• LinkedInlinkedin.com/company/voicemed
• Instagraminstagram.com/airlyn_app

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds3 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about VoiceMed